Skip to content

Study · Non-randomized trial · 2013

6 results

The addition of GnRH antagonists in intrauterine insemination cycles: a pilot study.

Graziano A, Caserta D, Piva I, Lo Monte G, Bordi G, Martini F, Tognon M, Marci R

European review for medical and pharmacological sciences1 Jun 2013Cited by 5 (Europe PMC)

PMID23832726 (opens in a new tab)PepBankPUB-23832726
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In IUI patients, cetrorelix did not significantly increase clinical pregnancy rates versus r-FSH only (18.05% versus 10.81%).

    In plain wordsIn IUI patients, cetrorelix did not significantly increase pregnancy rates compared with r-FSH only.

    Peptide
    Cetrorelix
    Outcome
    No significant changeClinical pregnancy rate
    Study

    n: not reported in source

    Comparator
    r-FSH only
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Measurements

    Clinical pregnancy rate
    18.05%
    cetrorelix
    Clinical pregnancy rate
    10.81%
    r-FSH only

    Source sentences

    Summary
    A trend towards higher PR in Group A was detected, although it was not statistically significant (Clinical PR: 18.05% vs 10.81%).
    5 context sentences
    Summary · context
    The primary outcome was clinical Pregnancy Rate (PR).
    Summary · context
    This prospective study was designed to assess whether the use of GnRH antagonists can improve the success rate of controlled ovarian stimulation (COS) in intrauterine insemination (IUI) treatments.
    Summary · context
    Eighty patients were divided into two groups: GnRH antagonist group (Group A, n=40) and control group (Group B, n=40).
    Summary · context
    Patients in Group B underwent COS with recombinant Follicle Stimulating Hormone (r-FSH, 50-75 IU/d) only, while patients in Group A were administered r-FSH (50-75 IU/d) plus cetrorelix (0.25 mg/d, starting when ≥ 2 follicles ≥ 14 mm were detected on ultrasound scan).
    Summary · context
    A total of 146 cycles were performed (Group A: n=72; Group B: n=74).
  2. 02HumanNon-randomized trialEfficacy outcome

    In IUI patients, cetrorelix significantly increased the number of follicles ≥16 mm versus r-FSH only.

    In plain wordsIn IUI patients, cetrorelix increased the number of follicles ≥16 mm compared with r-FSH only.

    Peptide
    Cetrorelix
    Outcome
    IncreaseFollicles ≥16 mm
    Study

    n: not reported in source

    Comparator
    r-FSH only
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Source sentences

    Summary
    The number of follicles ≥ 16 mm was significantly increased in Group A.
    5 context sentences
    Summary · context
    Secondary outcomes were ongoing PR, incidence of Premature Luteinization (PL), number of follicles with mean diameter ≥ 16 mm and between 11 and 15 mm on the day of hCG administration, miscarriage rate, cycle cancellation rate, total amount of r-FSH used and duration of treatment.
    Summary · context
    This prospective study was designed to assess whether the use of GnRH antagonists can improve the success rate of controlled ovarian stimulation (COS) in intrauterine insemination (IUI) treatments.
    Summary · context
    Eighty patients were divided into two groups: GnRH antagonist group (Group A, n=40) and control group (Group B, n=40).
    Summary · context
    Patients in Group B underwent COS with recombinant Follicle Stimulating Hormone (r-FSH, 50-75 IU/d) only, while patients in Group A were administered r-FSH (50-75 IU/d) plus cetrorelix (0.25 mg/d, starting when ≥ 2 follicles ≥ 14 mm were detected on ultrasound scan).
    Summary · context
    A total of 146 cycles were performed (Group A: n=72; Group B: n=74).
  3. 03HumanNon-randomized trialEfficacy outcome

    In IUI patients, cetrorelix significantly reduced premature luteinization incidence versus r-FSH only.

    In plain wordsIn IUI patients, cetrorelix reduced premature luteinization compared with r-FSH only.

    Peptide
    Cetrorelix
    Outcome
    DecreasePremature luteinization
    Study

    n: not reported in source

    Comparator
    r-FSH only
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Source sentences

    Summary
    The incidence of both premature LH surge and premature luteinization (PL) was significantly higher in Group B.
    4 context sentences
    Summary · context
    This prospective study was designed to assess whether the use of GnRH antagonists can improve the success rate of controlled ovarian stimulation (COS) in intrauterine insemination (IUI) treatments.
    Summary · context
    Eighty patients were divided into two groups: GnRH antagonist group (Group A, n=40) and control group (Group B, n=40).
    Summary · context
    Patients in Group B underwent COS with recombinant Follicle Stimulating Hormone (r-FSH, 50-75 IU/d) only, while patients in Group A were administered r-FSH (50-75 IU/d) plus cetrorelix (0.25 mg/d, starting when ≥ 2 follicles ≥ 14 mm were detected on ultrasound scan).
    Summary · context
    A total of 146 cycles were performed (Group A: n=72; Group B: n=74).
  4. 04HumanNon-randomized trialEfficacy outcome

    In IUI patients, stimulation duration did not differ significantly between cetrorelix and r-FSH only.

    In plain wordsIn IUI patients, stimulation duration did not differ significantly between cetrorelix and r-FSH only.

    Peptide
    Cetrorelix
    Outcome
    No significant changeStimulation duration
    Study

    n: not reported in source

    Comparator
    r-FSH only
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Source sentences

    Summary
    No significant differences were found in the duration of the stimulation protocol, and in the total amount of r-FSH administered.
    4 context sentences
    Summary · context
    This prospective study was designed to assess whether the use of GnRH antagonists can improve the success rate of controlled ovarian stimulation (COS) in intrauterine insemination (IUI) treatments.
    Summary · context
    Eighty patients were divided into two groups: GnRH antagonist group (Group A, n=40) and control group (Group B, n=40).
    Summary · context
    Patients in Group B underwent COS with recombinant Follicle Stimulating Hormone (r-FSH, 50-75 IU/d) only, while patients in Group A were administered r-FSH (50-75 IU/d) plus cetrorelix (0.25 mg/d, starting when ≥ 2 follicles ≥ 14 mm were detected on ultrasound scan).
    Summary · context
    A total of 146 cycles were performed (Group A: n=72; Group B: n=74).
  5. 05HumanNon-randomized trialEfficacy outcome

    In IUI patients, total r-FSH administration did not differ significantly between cetrorelix and r-FSH only.

    In plain wordsIn IUI patients, total r-FSH administration did not differ significantly between cetrorelix and r-FSH only.

    Peptide
    Cetrorelix
    Outcome
    No significant changeTotal r-FSH administered
    Study

    n: not reported in source

    Comparator
    r-FSH only
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Source sentences

    Summary
    No significant differences were found in the duration of the stimulation protocol, and in the total amount of r-FSH administered.
    4 context sentences
    Summary · context
    This prospective study was designed to assess whether the use of GnRH antagonists can improve the success rate of controlled ovarian stimulation (COS) in intrauterine insemination (IUI) treatments.
    Summary · context
    Eighty patients were divided into two groups: GnRH antagonist group (Group A, n=40) and control group (Group B, n=40).
    Summary · context
    Patients in Group B underwent COS with recombinant Follicle Stimulating Hormone (r-FSH, 50-75 IU/d) only, while patients in Group A were administered r-FSH (50-75 IU/d) plus cetrorelix (0.25 mg/d, starting when ≥ 2 follicles ≥ 14 mm were detected on ultrasound scan).
    Summary · context
    A total of 146 cycles were performed (Group A: n=72; Group B: n=74).
  6. 06HumanNon-randomized trialEfficacy outcome

    In IUI patients, cetrorelix significantly reduced premature LH surge incidence versus r-FSH only.

    In plain wordsIn IUI patients, cetrorelix reduced premature LH surges compared with r-FSH only.

    Peptide
    Cetrorelix
    Outcome
    DecreasePremature LH surge
    Study

    n: not reported in source

    Comparator
    r-FSH only
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Source sentences

    Summary
    The incidence of both premature LH surge and premature luteinization (PL) was significantly higher in Group B.
    4 context sentences
    Summary · context
    This prospective study was designed to assess whether the use of GnRH antagonists can improve the success rate of controlled ovarian stimulation (COS) in intrauterine insemination (IUI) treatments.
    Summary · context
    Eighty patients were divided into two groups: GnRH antagonist group (Group A, n=40) and control group (Group B, n=40).
    Summary · context
    Patients in Group B underwent COS with recombinant Follicle Stimulating Hormone (r-FSH, 50-75 IU/d) only, while patients in Group A were administered r-FSH (50-75 IU/d) plus cetrorelix (0.25 mg/d, starting when ≥ 2 follicles ≥ 14 mm were detected on ultrasound scan).
    Summary · context
    A total of 146 cycles were performed (Group A: n=72; Group B: n=74).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.